TENAX THERAPEUTICS, INC. — Income Charts
41 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
Cost of Revenue
$0
Gross Profit
$0
R&D↑+129.4% +$6M
$11M
SG&A↑+18.2% +$354K
$2M
D&A↓-100.0% -$5K
$0
Operating Income↓-263.8% -$12M
$-17M
EBITDA↓-263.8% -$12M
$-17M
Interest Expense
$0
Tax Provision
—
Net Income↓-299.0% -$12M
$-16M
Gross Margin
—
Operating Margin
784271.0%
Net Margin
784015.3%
Deferred Tax Liabilities
$239K
ETR (Continuing Operations)↓-21.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)
0.1%
Operating Lease Cost
$10K
Revenue YoY Variation↑+358.9pts
341.7%
Income YoY Variation↑+54.3pts
-263.8%
Revenue QoQ Variation↑+25.1pts
-74.9%
Income QoQ Variation↓-16.7pts
-42.5%